ERBB2 and breast cancer: Currently, based on numerous clinical trials, Lapatinib is used in association with several chemotherapeutic agents, such as capecitabine (Geyer et al., 2006) or trastuzumab (Blackwell et al., 2012) in patients with advanced HER2-positive breast cancer.